CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Immunotech Biopharm Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Immunotech Biopharm Ltd
8th Floor, Building 1
Guosheng Science and Technology Park
Beijing, BEJ  China Ticker: 69786978

Business Summary
Immunotech Biopharm Ltd is a China-based investment holding company mainly engaged in the research and development, manufacturing and commercialization of immune cell products for treatments of cancers. Its main products are EAL, CAR-T cell series and TCR-T cell series products. EAL is a multi-target cellular immunotherapy product. It also provides cell cryopreservation services. The Company mainly conducts its businesses in the domestic market.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/202312/31/2022Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the Board ZhengTan 44 8/1/2019 4/11/2018
Chief Executive Officer, Chief Technology Officer, Executive Director YuWang 54 8/23/2019 3/1/2019
Chief Financial Officer, Company Secretary NingYang 40 8/23/2021 4/1/2019
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 203 (As of 6/30/2023)
Outstanding Shares: 514,584,000 (As of 6/30/2023)
Stock Exchange: HKG


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024